Vanguard Fiduciary Trust
INTS icon

Vanguard Fiduciary Trust’s Intensity Therapeutics INTS Stock Holding History

Vanguard Fiduciary Trust’s Portfolio INTS Stock Details INTS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$37.4K Hold
9,121
– – ﹤0.01% 3920
2026
Q1 		$53.6K Buy
+9,121
New +$74.5K ﹤0.01% 3817

Other funds holding INTS

KWM
KMT Wealth Management El Segundo, California $118M AUM 26.19% 1-Year Est. Return
SL
Sentinus LLC Oak Brook, Illinois $1.25B AUM 22.33% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SC
Sapient Capital Indianapolis, Indiana $7.64B AUM 51.51% 1-Year Est. Return
NCNMGF
Nano-Cap New Millennium Growth Fund Staten Island, New York $130M AUM
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
MFIM
Mesirow Financial Investment Management Chicago, Illinois $6.37B AUM 23.22% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $4.08B AUM 58.77% 1-Year Est. Return
NA
NewEdge Advisors New Orleans, Louisiana $33.6B AUM 31.03% 1-Year Est. Return

Vanguard Fiduciary Trust's INTS Position: Q2 2026 in Review

Vanguard Fiduciary Trust held its Intensity Therapeutics (INTS) position steady in Q2 2026 at 9,121 shares worth $37.4K. The position accounts for ﹤0.01% of the portfolio, ranked #3920.

Vanguard Fiduciary Trust first reported a position in INTS in Q1 2026 and has held it in 2 quarters since. The position peaked at $53.6K in Q1 2026. 17 funds tracked by Wall St. Rank hold INTS as of Q2 2026.

  • Vanguard Fiduciary Trust held 9,121 shares of Intensity Therapeutics worth $37.4K as of Q2 2026.
  • Vanguard Fiduciary Trust left its Intensity Therapeutics share count unchanged in Q2 2026.
  • Intensity Therapeutics made up ﹤0.01% of Vanguard Fiduciary Trust's portfolio in Q2 2026, its #3920 holding.
  • Vanguard Fiduciary Trust first reported a position in Intensity Therapeutics in Q1 2026 and has held it in 2 quarters since.
  • Vanguard Fiduciary Trust's Intensity Therapeutics position peaked at $53.6K in Q1 2026.
  • 17 funds tracked by Wall St. Rank held Intensity Therapeutics as of Q2 2026.

Based on Vanguard Fiduciary Trust's 13F filing for Q2 2026, filed 13 Aug 2026.